Table 2.

Treatment-related AEs*†

	All treated patients, N=50	Progressed on prior anti-PD-1 therapy, n=33	No prior anti-PD-1 therapy, n=17
Treatment-related AEs	47 (94)	30 (91)	17 (100)
Grade ≥3 V937-related AEs	0	0	0
Grade 3 or 4 ipilimumab-related AEs‡§	7 (14)	4 (12)	3 (18)

Treatment-related AEs occurring in ≥10% of all treated patients	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4
Pruritus	25 (50)	1 (2)	17 (52)	0	8 (47)	1 (6)
Fatigue	22 (44)	1 (2)	15 (45)	0	7 (41)	1 (6)
Diarrhea	16 (32)	2 (4)	13 (39)	2 (6)	3 (18)	0
Nausea	11 (22)	0	9 (27)	0	2 (12)	0
Rash	10 (20)	0	5 (15)	0	5 (29)	0
Pyrexia	8 (16)	0	5 (15)	0	3 (18)	0
Chills	7 (14)	0	6 (18)	0	1 (6)	0
Influenza-like illness	7 (14)	0	6 (18)	0	1 (6)	0
Decreased appetite	6 (12)	0	5 (15)	0	1 (6)	0
Injection site reaction	6 (12)	0	3 (9)	0	3 (18)	0
Transaminase increase	6 (12)	0	5 (15)	0	1 (6)	0
Headache	5 (10)	0	5 (15)	0	0	0
Injection site pain	5 (10)	0	2 (6)	0	3 (18)	0

*Data are presented as n (%).

†Treatment-related AEs were those events with a V937 or ipilimumab relationship of possibly, probably, or definitely.

‡There were no grade 5 treatment-related AEs.

§The most common grade 3 and 4 treatment-related AEs were dehydration, diarrhea, and hepatotoxicity (two patients (4%) each).

AE, adverse event; anti-PD-1, antiprogrammed death 1.